Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 9:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 412 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Knee injection Clear all
Not listed Phase 2 Interventional

Phase II Study to Assess Safety and Efficacy of SL-1002 for Osteoarthritic Knee Pain

NCT05470608
View directory record Official record
Conditions
Osteoarthritis, Knee Pain
Interventions
SL-1002, Placebo
Drug
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
35 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
15
States / cities
Greenwood Village, Colorado • Washington D.C., District of Columbia • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis.

NCT03379168
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Microfragmented Adipose Tissue (Lipogems), Corticosteroid injection, Saline
Device · Drug
Lead sponsor
Dustin L. Richter, MD
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Feb 12, 2025 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA

NCT03378076
View directory record Official record
Conditions
Bilateral Knee Osteoarthritis
Interventions
FX006 32 mg, TAcs 40 mg
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
40 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Torrance, California • Rochester, New York • Duncansville, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 23, 2024 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 4 Interventional Results available

Management of Postoperative Pain After Total Knee Replacement.

NCT01163214
View directory record Official record
Conditions
Postoperative Pain, Knee Replacement Arthroplasty
Interventions
Nerve Block, Periarticular Injection
Drug
Lead sponsor
Mark J. Spangehl, M.D.
Other
Eligibility
18 Years to 79 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2014 · Synced Sep 4, 2026, 9:31 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Exparel vs Block for ACL Reconstruction

NCT06006624
View directory record Official record
Conditions
ACL, Postoperative Pain
Interventions
Exparel 30 mL, 0.5% bupivacaine, Dexamethasone, iPACK block
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Sep 4, 2026, 9:31 AM EDT
Terminated Phase 4 Interventional

ZYNRELEF for Pain Management in Total Knee Arthroplasty

NCT05644496
View directory record Official record
Conditions
Post Operative Pain, Osteoarthritis, Knee
Interventions
Bupivacaine-Meloxicam 400 Mg-12 Mg/14 mL Injectable Solution, Extended Release
Drug
Lead sponsor
Baptist Health South Florida
Other
Eligibility
35 Years to 70 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 3 Interventional Results available

Open-label Trial to Check the Safety and Tolerability of RTX-GRT7039 Injections for Pain Associated With Osteoarthritis of the Knee

NCT05377489
View directory record Official record
Conditions
Osteoarthritis
Interventions
RTX-GRT7039
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
714 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
27
States / cities
Glendale, Arizona • Phoenix, Arizona • Anaheim, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 4 Interventional

Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance

NCT05058209
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Triamcinolone acetonide extended-release injectable suspension, Betamethasone sodium phosphate and betamethasone acetate Injectable Suspension
Drug
Lead sponsor
ROC Foundation
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Reno, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 26, 2021 · Synced Sep 4, 2026, 9:31 AM EDT
Not listed Phase 1 Interventional

Evaluation of Safety and Exploratory Efficacy of an Autologous Adipose-derived Cell Therapy Product for Treatment of Single Knee Osteoarthritis

NCT04043819
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
PSC-01
Drug
Lead sponsor
Personalized Stem Cells, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Carlsbad, California • La Mesa, California • San Diego, California + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2020 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Not applicable Interventional

Injection of Autologous Adipose Tissue for Treatment of Osteoarthritis in the Knee

NCT03399630
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Injection of Autologous Adipose Tissue, Injection of lactated ringers
Other
Lead sponsor
Aestique Medical Center
Other
Eligibility
40 Years to 75 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
2
States / cities
Greensburg, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 4, 2026, 9:31 AM EDT
Terminated Phase 3 Interventional Results available

3-year, Open-Label Study Evaluating Safety, Tolerability, and Efficacy of Lorecivivint in Knee Osteoarthritis

NCT04931667
View directory record Official record
Conditions
Osteoarthritis of the Knee
Interventions
Lorecivivint
Drug
Lead sponsor
Biosplice Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
4
States / cities
Tucson, Arizona • Winter Park, Florida • Oak Brook, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Not applicable Interventional Results available

Can Single-Injection Adductor Canal Blocks Improve PostOp Pain Relief in Patients Undergoing Total Knee Arthroplasty?

NCT02276495
View directory record Official record
Conditions
Pain Management
Interventions
ACB Control - 20 ml saline injection for ACB, ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block, Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline
Other · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2024 · Synced Sep 4, 2026, 9:31 AM EDT
Terminated Phase 2 Interventional Results available

A Dose-Finding Study to Evaluate the Efficacy and Safety of GSK3858279 in Adults With Knee Osteoarthritis (OA) Pain

NCT05838742
View directory record Official record
Conditions
Pain, Osteoarthritis, Knee
Interventions
GSK3858279, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
314 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Cerritos, California • Huntington Beach, California • Santa Clara, California + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 9, 2025 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 4 Interventional Results available

Pilot Study Evaluating Alterations in Thrombogenicity and Platelet Reactivity Following Lower Extremity Arthroplasty

NCT01809054
View directory record Official record
Conditions
Primary Total Hip and Knee Arthroplasty
Interventions
Arixtra, Pneumatic compression stockings, Aspirin
Drug · Device
Lead sponsor
LifeBridge Health
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Not applicable Interventional

Platelet Rich Plasma Versus Corticosteroids in Knee Osteoarthritis Pain

NCT06703970
View directory record Official record
Conditions
Knee Osteoarthritis (OA)
Interventions
Corticosteroid Injection, Platelet Rich Plasma Joint Injection
Drug · Device
Lead sponsor
LifeBridge Health
Other
Eligibility
21 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 4, 2026, 9:31 AM EDT
Not listed Phase 2 Interventional

Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis

NCT04448106
View directory record Official record
Conditions
Osteoarthritis, Knee, Osteoarthritis, Hip, Osteoarthritis Shoulder
Interventions
Celltex- AdMSCs
Biological
Lead sponsor
Celltex Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 17, 2023 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

NCT04238598
View directory record Official record
Conditions
Knee Osteoarthritis
Interventions
Pulse Radiofrequency, Standard of Care Intra- Articular Injection, Placebo Intra-Articular Injection
Procedure
Lead sponsor
Center For Interventional Pain and Spine
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Exton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of MM-II for Treatment of Knee Pain in Subjects With Symptomatic Knee Osteoarthritis

NCT04506463
View directory record Official record
Conditions
Osteoarthritis of Knee
Interventions
MM-II dose I, MM-II dose II, MM-II dose III, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
40 Years to 99 Years
Enrollment
397 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
21
States / cities
Birmingham, Alabama • Tempe, Arizona • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 4 Interventional Results available

Comparing Post-Op Narcotic Usage in Patients Receiving Periarticular Exparel vs. Standard Periarticular Joint Inj

NCT02682498
View directory record Official record
Conditions
Arthroplasty, Replacement, Knee
Interventions
(Bupivacaine Liposome Injectable Suspension), Standard Preparation
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 1 Interventional

Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis

NCT02805855
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Autologous Adipose-Derived Mesenchymal Stromal Cells
Drug
Lead sponsor
Jacob L. Sellon, M.D.
Other
Eligibility
40 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 10, 2023 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 3 Interventional

Study of Efficacy, Safety of Fulranumab Adjunctive Use in OA of Hip or Knee, PAI3001

NCT02336685
View directory record Official record
Conditions
Osteoarthritis, Pain
Interventions
Placebo, Fulranumab 1 mg, Fulranumab 3 mg, Opioid
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 99 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Huntsville, Alabama • Cerritos, California + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 4, 2026, 9:31 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study Comparing Peri-articular Injection of Bupivacaine With and Without Epinephrine

NCT00737139
View directory record Official record
Conditions
Osteoarthritis
Interventions
Peri-articular injection of marcaine/epinephrine, Peri-articular injection of marcaine alone
Procedure
Lead sponsor
Rush University Medical Center
Other
Eligibility
19 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 30, 2012 · Synced Sep 4, 2026, 9:31 AM EDT
Not listed Phase 2 Interventional

Safety & Efficacy FloGraft (Micronized Human Amnion Chorion Membrane)® in Adults With Pain Due to OA of the Knee

NCT03441607
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
mHACMb, placebo
Drug · Other
Lead sponsor
Applied Biologics, LLC
Industry
Eligibility
30 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 27, 2018 · Synced Sep 4, 2026, 9:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Efficacy of Ipack Block and Surgeon's Joint Infiltration in Total Knee Arthroplasty

NCT03653416
View directory record Official record
Conditions
Osteo Arthritis Knee
Interventions
Ipack, Bupivacaine, Peri Articular Infiltration
Device · Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years to 75 Years
Enrollment
99 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Sep 4, 2026, 9:31 AM EDT